Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 1, 2006, Pages 89-95

  Trion, Astrid ^a,b   De Maat, Moniek ^b,c   Jukema, Wouter ^a   Maas, Annemarie ^b   Offerman, Erik ^b   Havekes, Louis ^a,b   Szalai, Alex ^d   Laarse, Arnoud Van Der ^a   Princen, Hans ^b   Emeis, Jef ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d University of Alabama at Birmingham   (United States)

Author keywords

Atherosclerosis; Calcium antagonist; Statins; Transgenic animal models

Indexed keywords

AMLODIPINE; APOLIPOPROTEIN E3; APOLIPOPROTEIN E3 LEIDEN; ATORVASTATIN; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE; SERUM AMYLOID A; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA ROOT; ARTICLE; CHOLESTEROL DIET; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRANSGENIC MOUSE; ANIMAL; ATHEROSCLEROSIS; BLOOD; BLOOD PRESSURE; DRUG COMBINATION; HUMAN; HYPERCHOLESTEROLEMIA; PATHOLOGY; PHYSIOLOGY;

AMLODIPINE; ANIMALS; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CHOLESTEROL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MICE; MICE, TRANSGENIC; PYRROLES; SERUM AMYLOID A PROTEIN; VON WILLEBRAND FACTOR;

EID: 33646682145     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000195603.65858.27     Document Type: Article

References (41)

1. McGill HC. Overview. In: Fuster V, Ross R, Topol EJ eds. Atherosclerosis and Coronary Artery Disease. Philadelphia: Lippincott-Raven; 2003;25-41.
2. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003;23:2155-2163.
3. Schachter M. Calcium antagonists and atherosclerosis. Int J Cardiol. 1997;62(Suppl 2):S9-15.
4. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet. 1990;335:1109-1113.
5. Waters D, Lesperance J, Francetich M, et al. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis. Circulation. 1990;82:1940-1953.
6. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102:1503-1510.
7. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2225.
8. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol. 2003;91:4B-8B.
9. Yoshida M. Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb. 2003;10:140-144.
10. Jukema JW, Zwinderman AH, van Boven AJ, et al. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler Thromb Vasc Biol. 1996;16:425-430.
11. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.
12. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002;106:1447-1452.
13. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230-235.
14. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 2001;103:1191-1193.
15. Kleemann R, Verschuren L, de Rooij BJ, et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood. 2004;103:4188-4194.
16. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, et al. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest. 1994;93:1403-1410.
17. Delsing DJ, Offerman EH, van Duyvenvoorde W, et al. Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation. 2001;103:1778-1786.
18. Delsing DJ, Jukema JW, van de Wiel MA, et al. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J Cardiovasc Pharmacol. 2003;42:63-70.
19. Volger OL, van Der BH, de Wit EC, et al. Dietary plant stanol esters reduce VLDL cholesterol secretion and bile saturation in apolipoprotein E*3-Leiden transgenic mice. Arterioscler Thromb Vasc Biol. 2001;21:1046-1052.
20. Ciliberto G, Arcone R, Wagner EF, et al. Inducible and tissue-specific expression of human C-reactive protein in transgenic mice. EMBO J. 1987;6:4017-4022.
21. Szalai AJ, Briles DE, Volanakis JE. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in transgenic mice. J Immunol. 1995;155:2557-2563.
22. Szalai AJ, van Ginkel FW, Dalrymple SA, et al. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. J Immunol. 1998;160:5294-5299.
23. Nishina PM, Verstuyft J, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 1990;31:859-869.
24. de Maat MP, de Bart AC, Hennis BC, et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol. 1996;16:1156-1162.
25. Ingerslev J. A sensitive ELISA for von Willebrand factor (vWf:Ag). Scand J Clin Lab Invest. 1987;47:143-149.
26. Gijbels MJ, van der Cammen M, van der Laan LJ, et al. Progression and regression of atherosclerosis in APOE3-Leiden transgenic mice: an immunohistochemical study. Atherosclerosis. 1999;143:15-25.
27. Nayler WG. Review of preclinical data of calcium channel blockers and atherosclerosis. J Cardiovasc Pharmacol. 1999;33(Suppl 2):S7-11.
28. Tulenko TN, Sumner AE, Chen M, et al. The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. Am Heart J. 2001;141:S1-11.
29. Betz E, Weiss HD, Heinle H, et al. Calcium antagonists and atherosclerosis. J Cardiovasc Pharmacol. 1991;18(Suppl 10):S71-S75.
30. Nilsson J, Sjolund M, Palmberg L, et al. The calcium antagonist nifedipine inhibits arterial smooth muscle cell proliferation. Atherosclerosis. 1985;58:109-122.
31. Nomoto A, Mutoh S, Hagihara H, et al. Smooth muscle cell migration induced by inflammatory cell products and its inhibition by a potent calcium antagonist, nilvadipine. Atherosclerosis. 1988;72:213-219.
32. Mak IT, Boehme P, Weglicki WB. Antioxidant effects of calcium channel blockers against free radical injury in endothelial cells. Correlation of protection with preservation of glutathione levels. Circ Res. 1992;70:1099-1103.
33. Tulenko TN, Brown J, Laury-Kleintop L, et al. Atheroprotection with amlodipine: cells to lesions and the PREVENT trial. Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial. J Cardiovasc Pharmacol. 1999;33(Suppl 2):S17-S22.
34. Eickelberg O, Roth M, Block LH. Effects of amlodipine on gene expression and extracellular matrix formation in human vascular smooth muscle cells and fibroblasts: implications for vascular protection. Int J Cardiol. 1997;62(Suppl 2):S31-S37.
35. Orekhov AN, Tertov VV, Sobenin IA, et al. Antiatherosclerotic and antiatherogenic effects of a calcium antagonist plus statin combination: amlodipine and lovastatin. Int J Cardiol. 1997;62(Suppl 2):S67-S77.
36. Kaneider NC, Reinisch CM, Dunzendorfer S, et al. Induction of apoptosis and inhibition of migration of inflammatory and vascular wall cells by cerivastatin. Atherosclerosis. 2001;158:23-33.
37. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002;22:300-305.
38. Kinlay S, Selwyn AP. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol. 2003;91:9B-13B.
39. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115-126.
40. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
41. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.